Pfizer is expected to report its third-quarter results next month, and analysts are projecting a double-digit decline in its ...

Have you been searching for a stock that might be well-positioned to maintain its earnings-beat streak in its upcoming report ...

During periods of economic uncertainty, investing in pharmaceutical companies demonstrates unique defensive characteristics.

Pfizer acquired a smaller company for $4.9 billion to improve its prospects in the GLP-1 market. The pharmaceutical giant could carve out a small niche for itself in this growing space. Pfizer's ...

Pfizer Inc. (NYSE: PFE) made a strong move higher after it became the first drug manufacturer to sign on as part of the ...

Pfizer Inc. has secured an MFN pricing deal with the White House, easing recent tariff and drug repricing concerns while affording a win for Trump. Learn more about PFE stock here.

Pfizer stock dipped after losses but analysts predict recovery, citing strong profitability, bullish momentum, and tariff reprieve.

Pfizer agreed to lower prescription drug costs for Medicaid and invest $70 billion in US manufacturing, President Trump ...

The GLP-1 market has grabbed considerable attention in the past couple of years, and there's little doubt as to which pharmaceutical companies dominate this space. Eli Lilly is currently the leader, ...